Squarepoint Ops LLC decreased its position in Recro Pharma Inc (NASDAQ:REPH) by 15.1% in the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 169,683 shares of the specialty pharmaceutical company’s stock after selling 30,137 shares during the period. Squarepoint Ops LLC’s holdings in Recro Pharma were worth $1,880,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Royal Bank of Canada purchased a new stake in Recro Pharma in the second quarter valued at $198,000. Acadian Asset Management LLC grew its holdings in shares of Recro Pharma by 6.1% in the second quarter. Acadian Asset Management LLC now owns 258,740 shares of the specialty pharmaceutical company’s stock valued at $2,631,000 after purchasing an additional 14,958 shares in the last quarter. JPMorgan Chase & Co. increased its position in shares of Recro Pharma by 43.4% during the second quarter. JPMorgan Chase & Co. now owns 148,946 shares of the specialty pharmaceutical company’s stock worth $1,436,000 after acquiring an additional 45,084 shares during the period. Engine Capital Management LP raised its position in Recro Pharma by 3.8% in the 2nd quarter. Engine Capital Management LP now owns 1,104,546 shares of the specialty pharmaceutical company’s stock valued at $11,233,000 after purchasing an additional 40,000 shares in the last quarter. Finally, BlackRock Inc. lifted its stake in Recro Pharma by 14.9% in the second quarter. BlackRock Inc. now owns 1,292,173 shares of the specialty pharmaceutical company’s stock worth $13,142,000 after acquiring an additional 167,346 shares during the last quarter. Institutional investors and hedge funds own 58.69% of the company’s stock.
Recro Pharma stock opened at $16.50 on Monday. The stock’s 50 day moving average price is $15.41 and its 200 day moving average price is $11.76. Recro Pharma Inc has a 1-year low of $5.53 and a 1-year high of $18.20. The company has a market cap of $369.37 million, a PE ratio of -6.63 and a beta of -0.35.
Recro Pharma (NASDAQ:REPH) last released its quarterly earnings data on Friday, November 8th. The specialty pharmaceutical company reported ($0.19) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.13) by ($0.06). The business had revenue of $25.26 million during the quarter, compared to analysts’ expectations of $19.83 million. Research analysts expect that Recro Pharma Inc will post -0.6 EPS for the current fiscal year.
REPH has been the subject of several recent analyst reports. BidaskClub upgraded Recro Pharma from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, October 22nd. ValuEngine lowered shares of Recro Pharma from a “buy” rating to a “hold” rating in a research note on Tuesday, December 3rd. Zacks Investment Research raised shares of Recro Pharma from a “hold” rating to a “buy” rating and set a $15.00 price objective on the stock in a report on Wednesday, October 30th. Finally, Stephens cut their price target on shares of Recro Pharma from $23.00 to $19.00 and set an “overweight” rating on the stock in a research note on Tuesday, November 26th. Two equities research analysts have rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $14.90.
Recro Pharma Company Profile
Recro Pharma, Inc, a specialty pharmaceutical company, develops and commercializes products for hospital and related acute care settings. The company operates in two segments, Acute Care, and Contract Development and Manufacturing. Its lead product candidate includes injectable meloxicam, which completed pivotal phase III clinical trials for the treatment of post-operative pain.
Featured Story: What are the qualifications of a portfolio manager?
Want to see what other hedge funds are holding REPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Recro Pharma Inc (NASDAQ:REPH).
Receive News & Ratings for Recro Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma and related companies with MarketBeat.com's FREE daily email newsletter.